Cargando…

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies

AIMS: Idarucizumab, a humanized monoclonal anti‐dabigatran antibody fragment, is effective in emergency reversal of dabigatran anticoagulation. Pre‐existing and treatment‐emergent anti‐idarucizumab antibodies (antidrug antibodies; ADA) may affect the safety and efficacy of idarucizumab. This analysi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Norris, Stephen, Ramael, Steven, Ikushima, Ippei, Haazen, Wouter, Harada, Akiko, Moschetti, Viktoria, Imazu, Susumu, Reilly, Paul A., Lang, Benjamin, Stangier, Joachim, Glund, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Drug Safety
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510069/ https://www.ncbi.nlm.nih.gov/pubmed/28230262 http://dx.doi.org/10.1111/bcp.13269

Ejemplares similares

Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study
por: Glund, Stephan, et al.
Publicado: (2016)

Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study
por: Yasaka, Masahiro, et al.
Publicado: (2017)

The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination
por: Glund, Stephan, et al.
Publicado: (2018)

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
por: Glund, Stephan, et al.
Publicado: (2019)

Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”
por: Glund, Stephan, et al.
Publicado: (2016)

Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism
por: Albisetti, Manuela, et al.
Publicado: (2017)

Idarucizumab for the treatment of dabigatran-related nephropathy
por: Alsamarrai, Ammar, et al.
Publicado: (2020)

Idarucizumab: A novel antidote for reversal of dabigatran
por: Rehman, Abdul, et al.
Publicado: (2016)

Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage
por: Balakumar, Jonathan, et al.
Publicado: (2017)

Risk of congenital anomalies in pregnant users of statin drugs
por: Ofori, Benjamin, et al.
Publicado: (2007)

First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials
por: Moehrle, Joerg J, et al.
Publicado: (2013)

Assessing the safety features of electronic patient medication record systems used in community pharmacies in England
por: Ojeleye, Oluwagbemileke, et al.
Publicado: (2014)

Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release
por: Eastwood, David, et al.
Publicado: (2013)

High dose droperidol and QT prolongation: analysis of continuous 12-lead recordings
por: Calver, Leonie, et al.
Publicado: (2014)

Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects
por: Green, Justin A, et al.
Publicado: (2014)

Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease
por: Renoux, Christel, et al.
Publicado: (2016)

QT interval prolongation in opioid agonist treatment: analysis of continuous 12‐lead electrocardiogram recordings
por: Isbister, Geoffrey K., et al.
Publicado: (2017)

Acid‐suppression medications and bacterial gastroenteritis: a population‐based cohort study
por: Wei, Li, et al.
Publicado: (2017)

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
por: Held, Valentin, et al.
Publicado: (2016)

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
por: Sié, Pierre
Publicado: (2016)

Dabigatran Toxicity in Acute Kidney Injury: Hemodialysis and Idarucizumab Required
por: McBride, Lucy, et al.
Publicado: (2018)

Idarucizumab for a traumatic head injury patient taking dabigatran
por: Maruyama, Shuhei, et al.
Publicado: (2018)

Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report
por: Kafke, Waldemar, et al.
Publicado: (2016)

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
por: Proietti, Marco, et al.
Publicado: (2018)

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
por: Abdulrehman, Jameel, et al.
Publicado: (2021)

Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects
por: Harada, Akiko, et al.
Publicado: (2019)

Safety and timing of resuming dabigatran after major gastrointestinal bleeding reversed by idarucizumab
por: Riario Sforza, Gian Galeazzo, et al.
Publicado: (2018)

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke
por: Hieber, Maren, et al.
Publicado: (2019)

Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
por: Gendron, Nicolas, et al.
Publicado: (2017)

Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature
por: Frol, Senta, et al.
Publicado: (2021)

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy
por: Kikule, Ilga, et al.
Publicado: (2022)

Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma
por: Edwards, Gail, et al.
Publicado: (2017)

Dabigatran level monitoring prior to idarucizumab administration in patients requiring emergent cardiac surgery
por: Litwinowicz, Radoslaw, et al.
Publicado: (2017)

Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution
por: Grottke, Oliver, et al.
Publicado: (2019)

First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab
por: Song, Steven, et al.
Publicado: (2017)

Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report
por: Tralhão, António, et al.
Publicado: (2017)

Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis
por: Fuhr, Laura Maria, et al.
Publicado: (2020)

Use of Idarucizumab to Revert the Anticoagulant Effect of Dabigatran in Heart Transplant Surgery: An Institutional Experience
por: Herrera-Escandón, Álvaro, et al.
Publicado: (2020)

Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
por: Ströhle, Mathias, et al.
Publicado: (2021)

Idarucizumab reverses dabigatran-induced anticoagulation in treatment of gastric bleeding: A case report
por: Jia, Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dpjsl6qm57q973qgm0i2rdtgkq